ANCA-associated vasculitis: Pathogenesis, novel markers of the disease and emerging therapies

Minerva Urologica e Nefrologica

Volumn 61, Issue 4, 2009, Pages 411-437

  Dhaygude, A ^a   Erdbruegger, U ^b   Haubitz, M ^c   Woywodt, A ^a  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF VIRGINIA   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Vasculitis, diagnosis; Vasculitis, drug therapy; Vasculitis, pathology

Indexed keywords

CYCLOPHOSPHAMIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; DISEASE ACTIVITY; DISEASE MARKER; ENDOTHELIUM CELL; ENDOTHELIUM LESION; INFECTION; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; REVIEW;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMANS; T-LYMPHOCYTES;

EID: 76449094708     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (225)

1. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomemlonephritis with antineutrophil anti-body: possible arbovirus aetiology? Br Med J (ClinResEd) 1982;285:606.
2. Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol 2008;20:55-60.
3. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512-23.
4. van der Woude FJ. Anticytoplasmic antibodies in Wegener's granulomatosis. Lancet 1985;2:48.
5. Woywodt A, Haubitz M, Haller H, Matteson EL. Wegener's granulomatosis. Lancet 2006;367:1362-6.
6. Rosen MJ. Dr. Friedrich Wegener and the ACCP, Revisited. Chest 2007;132:1723;discussion -4.
7. Witko-Sarsat V, Cramer EM, Hieblot C, Guichard J, Nusbaum P, Lopez S et al. Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules. Blood 1999:94:2487-96.
8. Griffith ME, Lovegrove JU, Gaskin G, Whitehouse DB, Pusey CD. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 1996;11:438-43.
9. Seo P, Stone JH. The antineutrophil cytoplasmic anti-body-associated vasculitides. Am J Med 2004;117:39-50.
10. Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 1995;123:925-32.
11. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998;53:743-53.
12. Flores-Suarez LF, Cabiedes J, Villa AR, van der Woude FJ, Alcocer-Varela J. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology (Oxford) 2003;42:223-9.
13. Schultz H, Heintz H, van Zandbergen G, Ullrich S, Reinhold-Keller E, Gross WL. ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient. Clin Exp Rheumatol 2003;21:763-6.
14. Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int 2000;57:846-62.
15. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004;93:398-401.
16. Silva F, Specks U, Sethi S, Irazabal MV, Fervenza FC. Successful pregnancy and delivery of a healthy new-born despite transplacental transfer of antimyeloper-oxidase antibodies from a mother with microscopic polyangiitis. AmJ Kidney Dis 2009;54:542-5.
17. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-33.
18. Tervaert JW, Huitema MG, Hene RJ, Sluiter WJ, The TH, van der Hem GK et al. Prevention of relapses in Wegener's granulomatosis by treatment based on anti-neutrophil cytoplasmic antibody titre. Lancet 1990;336:709-11.
19. Davenport A, Lock RJ, Wellington T. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immuno-fluorescence test. AmJ Nephrol 1995;15:201-7.
20. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neu-trophil cytoplasmic antibody concentration in longterm management of systemic vasculitis. Am J Kidney Dis 1995;25:380-9.
21. Langford CA. Antineutrophil cytoplasmic antibodies should not be used to guide treatment in Wegener's granulomatosis. Clin Exp Rheumatol 2004;22:S3-6.
22. Kiely PD, Gillespie KM, Oliveira DB. Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats. Eur J Immunol 1995;25:2899-906.
23. Neumann I, Birck R, Newman M, Schnulle P, Kriz W, Nemoto K et al. SCG/Kinjoh mice: a model of ANCA-associated crescentic glomerulonephritis with immune deposits. Kidney Int 2003;64:140-8.
24. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63.
25. Falk RJ, Jennette JC. ANCA Are pathogenic-oh yes they are! J Am Soc Nephrol 2002;13:1977-9.
26. Little MA, Smyth L, Salama AD, Mukherjee S, Smith J, Haskard D et al. Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoan-tibody-associated systemic vasculitis. Am J Pathol 2009;174:1212-20.
27. Pfister H, Ollert M, Fröhlich LF, Quintanilla-Martinez L, Colby TV, Specks U et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004;104:1411-8.
28. Kamesh L, Harper L, Savage CO. ANCA-Positive Vasculitis. J Am Soc Nephrol 2002;13:1953-60.
29. Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol 1997;8:386-94.
30. Pankhurst T, Savage CO, Little MA. Review article: Leukocyte-endothelial dysregulation in systemic small vessel vasculitis. Nephrology (Carlton) 2009.
31. Berger SP, Seelen MA, Hiemstra PS, Gerritsma JS, Heemskerk E, van der Woude FJ et al. Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. J Am Soc Nephrol 1996;7:694-701.
32. Taekema-Roelvink ME, van Kooten C, Janssens MC, Heemskerk E, Daha MR. Effect of anti-neutrophil cytoplasmic antibodies on proteinase 3-induced apoptosis of human endothelial cells. Scand J Immunol 1998;48:37-43.
33. Taekema-Roelvink ME, Kooten C, Kooij SV, Heemskerk E, Dana MR. Proteinase 3 enhances endothelial mono-cyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1. J Am Soc Nephrol 2001;12:932-40.
34. Pendergraft WF, 3rd, Rudolph EH, Falk RJ, Jahn JE, Grimmler M, Hengst L et al. Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. Kidney Int 2004;65:75-84.
35. Haller H, Eichhorn J Pieper K, Gobel U, Luft FC. Circulating leukocyte integrin expression in Wegener's granulomatosis. J Am Soc Nephrol 1996;7:40-8.
36. Calderwood JW, Williams JM, Morgan MD, Nash GB, Savage CO. ANCA induces beta2 integrin and CXC chemokine-dependent neutrophil-endothelial cell inter-actions that mimic those of highly cytokine-activated endothelium. J Leukoc Biol 2005;77:33-43.
37. Lou O, Alcaide P, Luscinskas FW, Muller WA. CD99 is a key mediator of the transendothelial migration of neutrophils. J Immunol 2007;178:1136-43.
38. Zhao T, Benard V, Bohl BP, Bokoch GM. The molecular basis for adhesion-mediated suppression of reactive oxygen species generation by human neutrophils. J Clin Invest 2003;112:1732-40.
39. Lu J, Zhu SM, Zang WJ, Xu XL, Luo HL, Yu XJ et al. Protective mechanism of adenosine to the rat arterial endothelial dysfunction induced by hydrogen peroxide. Biol Pharm Bull 2007;30:1206-11.
40. Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009;15:623-5.
41. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5.
42. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007;13:463-9.
43. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-7.
44. Bosch X. LAMPs and NETs in the pathogenesis of ANCA vasculitis. J Am Soc Nephrol 2009;20:1654-6.
45. Göbel U, Eichhorn J, Kettritz R, Briedigkeit L, Sima D, Lindschau C et al. Disease activity and autoantibodies to endothelial cells in patients with Wegener's granulomatosis. Am J Kidney Dis 1996;28:186-94.
46. Holmén C, Christensson M, Pettersson E, Bratt J, Stjärne P, Karrar A et al. Wegener's granulomatosis is associated with organ-specific antiendothelial cell antibodies. Kidney Int 2004;66:1049-60.
47. Fujieda M, Oishi N, Kurashige T. Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment. Clin Exp Immunol 1997;107:120-6.
48. Carvalho D, Savage CO, Isenberg D, Pearson JD. IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner. Arthritis Rheum 1999;42:631-40.
49. del Papa N, Meroni PL, Barcellini W, Sinico A, Radice A, Tincani A et al. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clin Immunol Immunopathol 1992;63:267-74.
50. Frampton G, Jayne DR, Perry GJ, Lockwood CM, Cameron JS. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol 1990;82:227-32.
51. Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol 2009;21:41-6.
52. Hu N, Westra J, Huitema MG, Stegeman CA, Limburg PC, Kallenberg CG. Autoantibodies against glomerular endothelial cells in anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Nephrology (Carlton) 2009;14:11-5.
53. Holmén C, Elsheikh E, Christensson M, Liu J, Johansson AS, Qureshi AR et al. Anti endothelial cell autoantibodies selectively activate SAPK/JNK signalling in Wegener's granulomatosis. J Am Soc Nephrol 2007;18:2497-508.
54. Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers. Am J Med 1983;74:700-4.
55. Hagen EC, de Keizer RJ, Andrassy K, van Boven WP, Bruijn JA, van Es LA et al. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995;43:351-9.
56. Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM 1996;89:903-12.
57. Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 1992;35:1088-96.
58. King WJ, Brooks CJ, Holder R, Hughes P, Adu D, Savage CO. T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission. Clin Exp Immunol 1998;112:539-46.
59. Csernok E, Trabandt A, Müller A, Wang GC, Moosig F, Paulsen J et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999;42:742-50.
60. Lúdvíksson BR, Sneller MC, Chua KS, Talar-Williams C, Langford CA, Ehrhardt RO et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998;160:3602-9.
61. Moosig F, Csernok E, Wang G, Gross WL. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin Exp Immunol 1998;114:113-8.
62. Webb LM, Feldmann M. Critical role of CD28/B7 costimulation in the development of human Th2 cytokine-producing cells. Blood 1995;86:3479-86.
63. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999;103:885-94.
64. Popa ER, Stegeman CA, Abdulahad WH, van der Meer B, Arends J, Manson WM et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007;46:1029-33.
65. Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2007;56:2080-91.
66. Jagiello P, Aries P, Anting L, Wagenleiter SE, Csernok E, Hellmich B et al. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005;52:4039-43.
67. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-77.
68. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2008;58:2196-205.
69. Abdulahad WH, Kallenberg CG, Limburg PC, Stegeman CA. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2830-8.
70. Voswinkel J, Assmann G, Held G, Pitann S, Gross WL, Holl-Ulrich K et al. Single cell analysis of B lymphocytes from Wegener's granulomatosis: B cell receptors display affinity maturation within the granulomatous lesions. Clin Exp Immunol 2008;154:339-45.
71. Mueller A, Holl-Ulrich K, Lamprecht P, Gross WL. Germinal centre-like structures in Wegener's granuloma: the morphological basis for autoimmunity? Rheumatology 2008;47:1111-3.
72. Voswinkel J, Muller A, Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci 2005;1051:12-9.
73. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005;25:298-302.
74. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999;96:6873-8.
75. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344-5.
76. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C et al. Inherited resistance to HIV-I conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial back-ground, and quantified risk. Mol Med 1997;3:23-36.
77. Zhou Y, Huang D, Farver C, Hoffman GS. Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener's granulomatosis. J Rheumatol 2003;30:1541-7.
78. Hogan SL, Satterly KK, Dooley MA, Nachman PH, Jennette JC, Falk RJ. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol 2001;12:134-42.
79. Hull CM, Couser WG, Knostman JD. A familial case of P-ANCA glomerulonephritis presenting in a father and daughter. Am J Kidney Dis 2000;35:E23.
80. Schreiber A, Busjahn A, Luft FC, Kettritz R. Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 2003;14:68-75.
81. Witko-Sarsat V, Lesavre P, Lopez S, Bessou G, Hieblot C, Prum B et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999;10:1224-33.
82. Tervaert JW, Popa ER, Bos NA. The role of superantigens in vasculitis. Curr Opin Rheumatol 1999;11:24-33.
83. Pendergraft WF, 3rd, Preston GA, Shah RR, Tropsha A, Carter CW Jr, Jennette JC et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004;10:72-9.
84. Kain R, Matsui K, Exner M, Binder S, Schaffner G, Sommer EM et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995;181:585-97.
85. Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008;14:1088-96.
86. Hedger N, Stevens J, Drey N, Walker S, Roderick P. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study. Nephrol Dial Transplant 2000;15:1593-9.
87. Ding M, Cui S, Li C, Jothy S, Haase V, Steer BM et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med 2006;12:1081-7.
88. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006;59:15-26.
89. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107:1761-7.
90. Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005;93:228-35.
91. Bardin N, George F, Mutin M, Brisson C, Horschowski N, Francés V et al. S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens 1996;48:531-9.
92. Woywodt A, Kirsch T, Haubitz M. Immunomagnetic isolation and FACS-competing techniques for the enumeration of circulating endothelial cells. Thromb Haemost 2006;96:1-2.
93. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003;361:206-10.
94. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: A novel marker of endothelial damage. Clin Chim Acta 2006;373:17-26.
95. Mancuso P, Calleri A, Cassi C, Gobbi A, Capillo M, Pruneri G et al. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003;522:83-97.
96. Mariucci S, Rovati B, Chatzileontiadou S, Bencardino K, Manzoni M, Delfanti S et al. A six-colour flow cytometric method for simultaneous detection of cell phenotype and apoptosis of circulating endothelial cells. Scand J Clin Lab Invest 2009:1-6.
97. Woywodt A, Blann AD, Kirsch T, et al. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 2006;4:671-7.
98. Mutin M, Canavy I, Blann A, Bory M, Sampol J, DignatGeorge F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999;93:2951-8.
99. Nadar SK, Up GY, Lee KW, Blann AD. Circulating endothelial cells in acute ischaemic stroke. Thromb Haemost 2005;94:707-12.
100. Dang A, Wang B, Li W, Zhang P, Liu G, Zheng D et al. Plasma endothelin-1 levels and circulating endothelial cells in patients with aortoarteritis. Hypertens Res 2000;23:541-4.
101. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Tokutomi T, Sekine I. Circulating endothelial cells in Kawasaki disease. Clin Exp Immunol 2003;131:536-40.
102. Clancy RM. Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Curr Rheumatol Rep 2000;2:39-43.
103. Foster W, Shantsila E, Carruthers D, Lip GY, Blann AD. Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction. Rheumatology (Oxford) 2009;48:285-8.
104. Erdbruegger U, Woywodt A, Kirsch T, Hallier H, Haubitz M. Circulating endothelial cells as a prognostic marker in thrombotic microangiopathy. Am J Kidney Dis 2006;48:564-70.
105. Haubitz M, Woywodt A. Circulating endothelial cells and vasculitis. Intern Med 2004;43:660-7.
106. Woywodt A, Goldberg C, Kirsch T, de Groot K, Erdbmegger U, Haller H et al. Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA-associated vasculitis. Ann Rheum Dis 2005;65:164-8.
107. Brogan PA, Shah V, Brachet C, Harnden A, Mant D, Klein N et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 20O4;50:927-36.
108. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res 2009;335:143-51.
109. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009;101:439-51.
110. Jy W, Horstman LL, Jimenez JJ, Ahn YS, Biró E, Nieuwland R et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004;2:1842-51.
111. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990;265:3809-14.
112. Erdbruegger U, Grossheim M, Hertel B, et al. Diagnostic role of endothelial microparticles in vasculitis. Rheumatology (Oxford) 2008;47:1820-5.
113. Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol 2007;66:159-65.
114. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998;161:4382-7.
115. Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem 1999;274:23111-8.
116. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002;99: 3962-70.
117. Lacroix R, Sabatier F, Mialhe A, Basire A, Pannell R, Borghi H et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood 2007.
118. Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 2000;95:1317-23.
119. Woywodt A, Erdbruegger U, Haubitz M. Circulating endothelial cells and endothelial progenitor cells after angioplasty: news from the endothelial rescue squad. J Thromb Haemost 2006;4:976-8.
120. Dzau VJ, Gnecchi M, Pachori AS, Morello F, Melo LG. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension 2005;46:7-18.
121. Mobius-Winkler S, Hollriegel R, Schuler G, Adams V. Endothelial progenitor cells: implications for cardiovascular disease. Cytometry A 2009;75:25-37.
122. Fadini GP, Baesso I, Albiero M, Sartore S, Agostini C, Avogaro A. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 2008;197:496-503.
123. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008;28:1584-95.
124. Eilken HM, Nishikawa S, Schroeder T. Continuous single-cell imaging of blood generation from haemogenic endothelium. Nature 2009;457:896-900.
125. de Groot K, Goldberg C, Bahlmann FH, Woywodt A, Haller H, Fliser D et al. Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2007;56:3847-53.
126. Avouac J, Juin F, Wipff J, Couraud PO, Chiocchia G, Kahan A et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis 2008;67:1455-60.
127. Holmén C, Elsheikh E, Stenvinkel P, Qureshi AR, Pettersson E, Jalkanen S et al. Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in patients with vasculitis and kidney involvement. J Am Soc Nephrol 2005;16:3110-20.
128. Zavada J, Kideryova L, Pytlik R, Vankova Z, Tesar V. Circulating endothelial progenitor cells in patients with ANCA-associated vasculitis. Kidney Blood Press Res 2008;31:247-54.
129. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921-6.
130. Matsumura M, Fukuda N, Kobayashi N, Umezawa H, Takasaka A, Matsumoto T et al. Effects of atorvastatin on angiogenesis in hindlimb ischemia and endothelial progenitor cell formation in rats. J Atheroscler Thromb 2009;16:319-26.
131. Rössig L, Urbich C, Brühl T, Dernbach E, Heeschen C, Chavakis E et al. Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells. J Exp Med 2005;201:1825-35.
132. Woywodt A, Bahlmann FH, de Groot K, Haller H, Haubitz M. Circulating endothelial cells: Life, death and detachment of the endothelial cell layer. Nephrol Dial Transplant 2002;17:1728-30.
133. Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, Ouaaz F et al. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001;166:7128-35.
134. van Rossum AP, Limburg PC, Kallenberg CG. Activation, apoptosis, and clearance of neutrophils in Wegener's granulomatosis. Ann N Y Acad Sci 2005;1051:1-11.
135. Chen Q, Stone PR, McCowan LM, Chamley LW. Phagocytosis of necrotic but not apoptotic trophoblasts induces endothelial cell activation. Hypertension 2006;47:116-21.
136. Kirsch T, Woywodt A, Beese M, Wyss K, Park JK, Erdbruegger U et al. Engulfment of apoptotic cells by microvascular endothelial cells induces proin-flammatory responses. Blood 2007;109:2854-62.
137. Yang JJ, Preston GA, Alcorta DA, Waga I, Munger WE, Hogan SL et al. Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoanti-bodies (ANCA). Kidney Int 2002;62:1638-49.
138. Mayet W, Schwarting A, Barreiros AP, Schlaak J, Neurath M. Anti-PR-3 antibodies induce endothelial IL-8 release. Eur J Clin Invest 1999;29:973-9.
139. Bonnefoy A, Moura R, Hoylaerts MF. The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 2008;65:713-27.
140. Kirsch T, Woywodt A, Klose J, Wyss K, Beese M, Erdbruegger U et al. Endothelial-derived throm-bospondin-1 promotes macrophage recruitment and apoptotic cell clearance. J Cell Mol Med 2009Jun 5. [Epub ahead of print].
141. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
142. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
143. Merkel PA, Cuthbertson DD, Hellmich B, Hoffman GS, Jayne DR, Kallenberg CG et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 2009;68:103-6.
144. Watts RA, Scott DG. Recent developments in the classification and assessment of vasculitis. Best Pract Res Clin Rheumatol 2009;23:429-43.
145. Fauci AS, Haynes B, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 1978;89:660-76.
146. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958;2:265-70.
147. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004-10.
148. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH et al. Outcome of ANCA-associated renai vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776-84.
149. Hoganson DD, From AM, Michet CJ. ANCA vasculitis in the elderly. J Clin Rheumatol 2008;14:78-81.
150. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002;100:82-5.
151. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
152. Haubitz M, Ehlerding C, Kamino K, Koch KM, Brunkhorst R. Reduced gonadal toxicity after i.v. cyclophosphamide administration in patients with nonmalignant diseases. Clin Nephrol 1998;49:19-23.
153. Kaplan MJ. Premature vascular damage in systemic lupus erythematosus. Autoimmunity 2009:1.
154. Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007;34:70-5.
155. Pagnoux C, Chironi G, Simon A, Guillevin L. Atherosclerosis in ANCA-associated vasculitides. Ann N Y Acad Sci 2007;1107:11-21.
156. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-7.
157. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
158. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:403-10.
159. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
160. Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-44.
161. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90:401-9.
162. de Groot K, Harper L, Jayne DRW, Flores Suarez LF, Gregorini G, Gross WL et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
163. de Groot K, Jayne D. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 2005;64:480-4.
164. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené
165. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352: 351-61.
166. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003;42:1149-53.
167. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.
168. Gottschlich S, Ambrosch P, Kramkowski D, Laudien M, Buchelt T, Gross WL et al. Head and neck manifestations of Wegener's granulomatosis. Rhinology 2006;44:227-33.
169. De Groot K Fau - Rasmussen N, Rasmussen N FauBacon PA, Bacon Pa Fau - Tervaert JWC et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
170. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008;23:1307-12.
171. Woywodt A, Goebel U. Bronchial stenosis and extensive bronchiectasis due to Wegener's granulomatosis. Nephron 2000;85:366-7.
172. Polychronopoulos VS, Prakash UB, Golbin JM, Edell ES, Specks U. Airway involvement in Wegener's granulomatosis. Rheum Dis Clin North Am 2007;33:755-75, vi.
173. Nouraei SA, Obholzer R, Ind PW, Salama AD, Pusey CD, Porter F et al. Results of endoscopic surgery and intralesional steroid therapy for airway compromise due to tracheobronchial Wegener's granulomatosis. Thorax 2008;63:49-52.
174. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803.
175. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007;46:1087-91.
176. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999;10: 1965-71.
177. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004;51:278-83.
178. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004;43:315-20.
179. Metzler C, Arlt AC, Gross WL, Brandt J. Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide. Ann Rheum Dis 2005;64:1798-800.
180. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (CANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004;51:269-73.
181. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16-20.
182. Lovric S, Erdbruegger U, Kümpers P, Woywodt A, Koenecke C, Wedemeyer H et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-asso-ciated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009;24:179-85.
183. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156-68.
184. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009;10:816-24.
185. Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009;34:328-35.
186. Aries PM, Hellmich B, Voswinkel J, Both M, Nölle B, Holl-Ulrich K et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853-8.
187. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D et al. Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W Mice. J Exp Med 2004;199:1577-84.
188. Cassese G, Lindenau S, de Boer B, Arce S, Hauser A, Riemekasten G et al. Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 2001;31:2726-32.
189. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-3.
190. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066-73.
191. Assi LK, Wong SH, Ludwig A, Raza K, Gordon C, Salmon M et al. Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum 2007;56:1776-86.
192. Lamprecht P. Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Clin Exp Immunol 2005;141:201-10.
193. Suzuki S. Deoxyspergualin. Mode of action and clinical trials. Ann N Y Acad Sci 1993;696:263-9.
194. Flossmann O, Baslund B, Bruchfeld A, Cohen Tervaert JW, Hall C et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009;68:1125-30.
195. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grünke M et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7.
196. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004;65:1440-8.
197. Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs 2003;63:1229-43; discussion 45-6.
198. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm anti-body associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008;67:1322-7.
199. Zhou Y, Huang D, Paris PL, Sauter CS, Prock KA, Hoffman GS. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum 2004;50:2645-50.
200. Reynolds J, Tam FW, Chandraker A, et al. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 2000;105:643-51.
201. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al. Cytokine Storm in a Phase 1 Trial of the Anti-CD 28 Monoclonal Antibody TGN1412. N Engl J Med 2006;355:1018-28.
202. Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993;43:682-92.
203. Huugen D, van Esch A, Xiao H, Peutz-Kootstra CJ, Buurman WA, Tervaert JW et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007;71:646-54.
204. Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. AmJ Pathol 2005;167:47-58.
205. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic anti-body-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.
206. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-54.
207. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006;54:1608-18.
208. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002;61:559.
209. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C et al. Efficacy of the anti-TNF-alpha anti-body infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126-32.
210. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002;41:1303-7.
211. Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30.
212. Elbek O, Uyar M, Aydin N, Börekçi S, Bayram N, Bayram H et al. Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. Clin Rheumatol 2009;28:421-6.
213. Osterman MT, Lichtenstein GR. Infliximab in fistulizing Crohn's disease. Gastroenterol Clin North Am 2006;35:795-820.
214. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215-28.
215. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2008.
216. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH et al. Clinical and biologic effects of anti-interleukin-10 monoclonal anti-body administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800.
217. Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991;337:1137-9.
218. Van Timmeren MM, Chen M, Heeringa P. Review article: Pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Nephrology (Carlton) 2009;14:16-25.
219. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009;20:289-98.
220. Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009:360: 542-4.
221. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006;116:2633-42.
222. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000;287:1049-53.
223. Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005;11:936-43.
224. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007;5:577-82.
225. Woywodt A, Kirsch T, Haubitz M. Circulating endothelial cells in renal disease: markers and mediators of vascular damage. Nephrol Dial Transplant 2008;23:7-10.